Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

3.620 -0.230 (-5.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,165,946
Open 3.700
Bid (Size) 3.520 (9)
Ask (Size) 4.000 (30)
Prev. Close 3.850
Today's Range 3.460 - 3.740
52wk Range 3.460 - 9.305
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors 
From Climb Bio, Inc.
Via GlobeNewswire
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
From Verve Therapeutics
Via GlobeNewswire

Performance

YTD
-39.8%
-39.8%
1 Month
-44.7%
-44.7%
3 Month
-42.0%
-42.0%
6 Month
-27.6%
-27.6%
1 Year
-58.3%
-58.3%

More News

Read More
Analyst Scoreboard: 4 Ratings For Verve Therapeutics
Via Benzinga
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
Via Investor's Business Daily
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
From The Rosen Law Firm PA
Via GlobeNewswire
VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV
From The Rosen Law Firm, P.A.
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and iLearningEngines and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and iLearningEngines and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – VERV
From The Rosen Law Firm PA
Via GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Verve Therapeutics, Inc. - Common Stock publicly traded?
Yes, Verve Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Verve Therapeutics, Inc. - Common Stock trade on?
Verve Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verve Therapeutics, Inc. - Common Stock?
The ticker symbol for Verve Therapeutics, Inc. - Common Stock is VERV on the Nasdaq Stock Market
What is the current price of Verve Therapeutics, Inc. - Common Stock?
The current price of Verve Therapeutics, Inc. - Common Stock is 3.620
When was Verve Therapeutics, Inc. - Common Stock last traded?
The last trade of Verve Therapeutics, Inc. - Common Stock was at 04/04/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.